ziprazidone

PreclinicalSmall molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

ziprazidone is one of 4 small molecule programs targeting PET. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PETCompleted

PETPreclinical

Completed

Competition

Competitive Landscape

4 competitors in PET

#DrugCompanyPhaseTrials

F-Arag

CCellSight Technologies, Inc.

Phase 2

1 2

F-18FDG

NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Phase 3

1 3

XBD173

Novartis

Preclinical

1 4

ziprazidone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral1 trial

12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients

Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00159757·150 enrolled

PET1 trial

24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study

Completed·CCentre for Addiction and Mental Health·N/A·NCT00818298·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ziprazidone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ziprazidone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ziprazidone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

ziprazidone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral1 trial

PET1 trial

References

Drug Info

Quick Facts

Related News